Revive Therapeutics (CSE: RVV) this morning has continued its push towards studying Bucillamine as a treatment for infectious diseases. Revive announced this morning that it has selected the contract research organization (CRO) that will be utilized to further clinical trials in the Asia-Pacific region.
Revive has selected Novotech as its CRO within the APAC region of the globe to further pursue exploring the use of Bucillamine. The company will work in conjunction with the firms US-based contract researcher, Pharm-Olam, to explore conducting phase 2 clinical trials on the drug for the purpose of treating infectious disease.
Notably, Bucillamine has been used for over thirty years in the Asia Pacific region as a treatment for arthritis. The result is that it has a known and recognized safety profile within the region. The company currently intends to focus on Japan and South Korea within the APAC region for further investigating Bucillamine.
We are pleased to have Novotech as part of our team to support us in our global clinical strategy for Bucillamine in infectious diseases, which includes COVID-19, and they will work in parallel and complement our initiatives in the U.S., specifically with our recently announced FDA pre-IND meeting request for Bucillamine. We have assembled an exemplary team of scientific, clinical and regulatory experts with Dr. David Boulware, MD as our scientific advisor, Dr. Kelly McKee, Jr., MD, MPH as Chief Scientific Officer consultant, Dr. Onesmo Mpanju, PhD as FDA Regulatory Affairs consultant, and now with Novotech as our APAC CRO. Novotech will assist our team in exploring the potential for a Phase 2 clinical study for Bucillamine in the treatment of infectious diseases in the APAC region.
Michael Frank, Revive’s Chief Executive Officer
Revive Therapeutics last traded at $0.11 on the CSE.
Sponsored · PTX Metals Inc.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
